Circular RNA Genomics in Cardiovascular Biology

Abstract

Circular RNAs (circRNAs) have emerged as a crucial class of non-coding RNAs with significant roles in cardiovascular biology. Recent advances in genomics have revealed that circRNAs are abundant, stable, and functionally diverse molecules, influencing gene expression, cellular signaling, cardiac development, and disease pathogenesis. This review synthesizes current evidence on circRNA biogenesis, epidemiological relevance, molecular mechanisms, clinical features associated with dysregulated circRNA profiles, diagnostic potential, therapeutic implications, and guideline-based recommendations for integrating circRNA research into cardiovascular practice. We highlight recent discoveries, ongoing clinical trials, and future directions, emphasizing the translational potential and challenges for clinicians and researchers in this rapidly evolving field.

Introduction

The cardiovascular system is subject to intricate regulatory networks involving coding and non-coding RNAs. Among these, circular RNAs (circRNAs) have gained prominence due to their covalently closed loop structures, conferring high stability and unique regulatory capacities. Initially considered splicing byproducts, circRNAs are now recognized for their tissue- and disease-specific expression patterns and functional relevance in cardiac physiology and pathology. With the advent of high-throughput sequencing and advanced bioinformatics, our understanding of circRNA genomics has expanded, revealing their participation in transcriptional and post-transcriptional regulation, including microRNA (miRNA) sponging, RNA-binding protein (RBP) interactions, and modulation of parental gene expression. This review provides a comprehensive overview of the current landscape of circRNA genomics in cardiovascular biology, focusing on mechanistic insights, epidemiology, clinical features, and therapeutic prospects for cardiovascular diseases (CVDs).

Epidemiology / Disease Burden

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide, with complex etiologies involving genetic, epigenetic, and environmental factors. Recent epidemiological studies have identified circRNA expression profiles as potential biomarkers for various CVDs, including coronary artery disease, heart failure, myocardial infarction, and arrhythmias. Large-scale transcriptomic analyses from patient cohorts and biobanks have demonstrated altered circRNA signatures in individuals with CVD compared to healthy controls, correlating with disease severity, prognosis, and response to treatment. The stability of circRNAs in blood and other bodily fluids enhances their utility as non-invasive biomarkers, underscoring their potential in risk stratification and epidemiological surveillance.

Pathophysiology

CircRNAs regulate cardiovascular physiology through diverse mechanisms. Biogenesis occurs via back-splicing of precursor mRNA, often regulated by cis-acting elements and RBPs. Functionally, circRNAs can act as miRNA sponges, sequestering miRNAs and preventing their interaction with target mRNAs. For example, circRNA Cdr1as inhibits miR-7, affecting apoptosis and hypertrophy in cardiomyocytes. Other circRNAs interact with proteins to modulate signaling cascades, such as circ-Foxo3 binding to CDK2 and p21, influencing cell cycle progression and senescence. Emerging evidence also suggests circRNAs can modulate transcription and translation, and some even encode small peptides. Their dysregulation contributes to pathogenesis by altering gene networks involved in inflammation, fibrosis, angiogenesis, and metabolic remodeling.

Risk Factors

CircRNA expression is influenced by both intrinsic and extrinsic risk factors. Genetic variants, such as single nucleotide polymorphisms in circRNA loci, may predispose individuals to altered circRNA profiles and heightened CVD risk. Epigenetic modifications, aging, sex hormones, and comorbidities such as diabetes, hypertension, and dyslipidemia impact circRNA regulation. Environmental exposures, including smoking, diet, and stress, have also been linked to circRNA expression changes. Understanding these risk determinants is essential for developing personalized cardiovascular risk assessments incorporating circRNA biomarkers.

Clinical Features

Dysregulated circRNAs have been associated with distinct clinical phenotypes. For instance, elevated circRNA_000203 is linked to cardiac fibrosis, while circRNA MICRA levels predict left ventricular dysfunction post-myocardial infarction. Some circRNAs correlate with arrhythmogenic risk, heart failure progression, and response to therapeutic interventions. Clinical studies are increasingly validating circRNAs as prognostic indicators and therapeutic targets, with specific signatures distinguishing acute coronary syndromes from stable disease, or ischemic from non-ischemic cardiomyopathies.

Diagnosis

Detection of circRNAs in blood, plasma, or tissue samples leverages quantitative PCR, RNA-sequencing, and microarray platforms. Their circular structure renders them resistant to exonucleases, enhancing their stability in clinical specimens. Diagnostic panels incorporating circRNA signatures have demonstrated high sensitivity and specificity for early detection of myocardial infarction, heart failure, and other CVDs. Integration of circRNA data with other omics and clinical variables enhances diagnostic accuracy and enables precision medicine approaches. However, standardization of assay protocols and validation in diverse populations remain key challenges.

Treatment & Management

Therapeutic modulation of circRNAs is an emerging frontier. Strategies include antisense oligonucleotides to silence pathogenic circRNAs, small molecules targeting circRNA biogenesis, and gene editing techniques such as CRISPR/Cas systems. Preclinical models have shown that targeting circRNA_010567 or circ-Foxo3 ameliorates cardiac hypertrophy and fibrosis. Additionally, circRNA mimics or delivery systems may enhance cardioprotective effects. Translation to clinical practice is ongoing, with several investigational therapies in early-phase clinical trials. Personalized medicine approaches may leverage individual circRNA profiles to guide therapeutic decisions and monitoring.

Recent Advances / Emerging Therapies

Recent advances include the development of circRNA-specific sequencing technologies, bioinformatics tools for functional annotation, and high-throughput screening platforms for drug discovery. Novel delivery systems, such as exosome-mediated circRNA transport, are being explored for targeted therapy. Clinical trials are evaluating the efficacy of antisense-based approaches in patients with heart failure and myocardial infarction. The integration of artificial intelligence and machine learning enhances the predictive value of circRNA-based algorithms for diagnosis and prognosis. As more circRNAs are functionally characterized, their roles as both biomarkers and therapeutic agents in cardiovascular medicine continue to expand.

Guideline Recommendations

While no major cardiology society guidelines currently mandate circRNA testing or therapy, consensus statements from expert panels advocate for the incorporation of circRNA research into clinical trials and biomarker discovery initiatives. Recommendations emphasize the need for multicenter validation, cross-platform standardization, and ethical considerations in clinical translation. Ongoing updates from professional societies are anticipated as evidence accumulates and regulatory frameworks evolve.

Conclusion

Circular RNA genomics represents a transformative frontier in cardiovascular biology, offering new insights into disease mechanisms, risk stratification, diagnostics, and therapeutics. While significant progress has been made, further research is required to standardize methodologies, validate clinical applications, and overcome translational hurdles. Collaboration between researchers, clinicians, and industry stakeholders will be pivotal in harnessing the full potential of circRNAs to improve cardiovascular outcomes. The integration of circRNA-based strategies into routine practice heralds a new era of precision medicine in cardiology.